Peptides · Regulatory
The 2026 peptide landscape: what's legal now, and what July could change
BPC-157, TB-500, and the PCAC review — a clear, honest map of what a provider can prescribe today versus what's still under FDA review.
Read →Latest
Hormones · Women's health
Perimenopause: the signs people miss, and when to talk to a provider
The transition starts earlier and looks broader than most expect. What's common, what the science says, and how to get a real evaluation.
Read →More, coming soon
Upcoming topics: TRT and what your labs actually mean · Peptides and recovery for athletes · Bioidentical vs. synthetic hormones · How supervised care differs from the gray market · Understanding 503A vs. 503B pharmacies. Want a topic covered? Email info@ReLyfe.health.
Have a question this didn't answer?
The best answer comes from a licensed provider. Start your confidential assessment — no obligation.
Take your assessment →This article is general education, not medical advice, diagnosis, or treatment, and does not create a provider–patient relationship. Statements describe areas of research and common experience, not proven results for any individual. Whether any therapy is appropriate is decided solely by a licensed provider after evaluation. Compounds under FDA review are not sold and are offered only via an early-access list. Relyfe / Quantum Recovery LLC is a telehealth and brand platform, is not a pharmacy, and does not itself prescribe or dispense.